The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | AML post-transplant maintenance: enasidenib & ivosidenib
Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA outlines the findings of two dose-escalation and expansion studies. One of the trials investigated the use of the IDH1 inhibitor ivosidenib in IDH1-mutated acute myeloid leukemia (AML) patients. The other looked at the use of enasidenib (ENA) in IDH2-mutated AML. Both trials investigate these regimens in the post-transplant maintenance setting. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
